severe cardiovascular artery disease
Conditions
Interventions
Trade Name: Glucophage 850mg
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: METFORMIN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 662.9-
Trade Na
Sponsors
University of Leipzig
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: -either impaired glucose tolerance (2h plasma glucose concentration >7.8 and 6.0 and 25 -severe coronary artery disease determined by coronary angiography -male patients aged 35-75 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: -diabetes mellitus type I -diabetes mellitus type II in combination with glycosylates hemoglobin >6.0%, previous medication with oral antidiabetic agents or insulin, fasting plasma glucose concentration >11.0mmol/L -unstable Angina pectoris -myocardial infarction within the last 4 weeks -reduced left-ventricular systolic function <30%
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: change in endothelial function in severe coronary artery disease;Secondary Objective: change in metabolic parameters;Primary end point(s): Change in endothelial function | — |
Countries
Germany
Outcome results
None listed